Vaccination therapy in prostate cancer

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2007-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00262-006-0233-8PMID 17031640PMCID PMC11030671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer.

  2019cited by this paper
• Vaccination of hormone‐refractory prostate cancer patients with peptide cocktail‐loaded dendritic cells: Results of a phase I clinical trial

  2006cited by this paper
• Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma

  2006cited by this paper
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

  2006cited by this paper
• A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

  2006cited by this paper
• Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.

  2006cited by this paper
• A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

  2006cited by this paper
• Tumor‐related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte‐colony stimulating factor (GM‐CSF)

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• STEAP, a prostate tumor antigen, is a target of human CD8+ T cells

  2006cited by this paper
• Tumor escape mechanisms in prostate cancer

  2006cited by this paper
• New epitope peptides derived from parathyroid hormone‐related protein which have the capacity to induce prostate cancer‐reactive cytotoxic T lymphocytes in HLA‐A2+ prostate cancer patients

  2005cited by this paper
• Immunoprevention and immunotherapy of cancer in ageing

  2005cited by this paper
• Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.

  2005cited by this paper
• Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer 1

  2005cited by this paper
• A listing of human tumor antigens recognized by T cells: March 2004 update

  2005cited by this paper
• Identification of Peptide Vaccine Candidates for Prostate Cancer Patients with HLA-A3 Supertype Alleles

  2005cited by this paper
• Identification of HLA-DRB1*1501–Restricted T-cell Epitopes from Prostate-Specific Antigen

  2005cited by this paper
• Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape.

  2005cited by this paper
• A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.

  2005cited by this paper
• Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers

  2005cited by this paper
• Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.

  2005cited by this paper
• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  2005cited by this paper
• Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.

  2005cited by this paper
• Is prostate-specific membrane antigen a multifunctional protein?

  2005cited by this paper
• Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

  2005cited by this paper
• Expression patterns of potential therapeutic targets in prostate cancer

  2005cited by this paper
• Recognition of Prostate and Breast Tumor Cells by Helper T Lymphocytes Specific for a Prostate and Breast Tumor-Associated Antigen, TARP

  2005cited by this paper
• Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer

  2005cited by this paper
• Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.

  2005cited by this paper
• Activation of Thymic Regeneration in Mice and Humans following Androgen Blockade

  2005cited by this paper
• Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions.

  2005cited by this paper
• Tumor-infiltrating T cells--friend or foe of neoplastic cells?

  2005cited by this paper
• Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2+ patients with hormone-refractory prostate cancer

  2004cited by this paper
• Phase I trial of patient‐oriented vaccination in HLA‐A2‐positive patients with metastatic hormone‐refractory prostate cancer

  2004cited by this paper
• Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells

  2004cited by this paper
• Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein

  2004cited by this paper
• Human CTLs to Wild-Type and Enhanced Epitopes of a Novel Prostate and Breast Tumor-Associated Protein, TARP, Lyse Human Breast Cancer Cells

  2004cited by this paper
• Manipulating dendritic cell biology for the active immunotherapy of cancer.

  2004cited by this paper
• Mechanisms and functional significance of tumour-induced dendritic-cell defects

  2004cited by this paper
• Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development.

  2004cited by this paper
• Vaccinia as a vector for gene delivery

  2004cited by this paper
• Increased incidence of pathological and clinical prostate cancer with age: age related alterations of local immune surveillance.

  2004cited by this paper
• Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis

  2004cited by this paper
• Generation of cytotoxic T lymphocytes specific for the prostate and breast tissue antigen TARP

  2004cited by this paper
• Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.

  2004cited by this paper
• Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Immunological monitoring during combination of patient‐oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer

  2004cited by this paper
• Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.

  2004cited by this paper
• Phase II Trial of GM-CSF in Advanced Prostate Cancer

  2004cited by this paper
• Commentary: Is prostate cancer an infectious disease?

  2004cited by this paper
• CD4 and CD8 T-Lymphocyte Recognition of Prostate Specific Antigen in Granulomatous Prostatitis

  2004cited by this paper
• Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trial

  2004cited by this paper
• Tumour-educated macrophages promote tumour progression and metastasis

  2004cited by this paper
• A prostate stem cell antigen‐derived peptide immunogenic in HLA‐A24− prostate cancer patients

  2004cited by this paper
• The promise of cancer vaccines

  2004cited by this paper
• Christianity and Democracy: The Global Picture

  2004cited by this paper
• Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors

  2003cited by this paper
• Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.

  2003cited by this paper
• Cytotoxic T-cell precursor frequencies to HER-2 (369 – 377) in patients with HER-2/neu-positive epithelial tumours

  2003cited by this paper
• Biology of prostate-specific antigen.

  2003cited by this paper
• Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.

  2003cited by this paper
• Cancer vaccines: between the idea and the reality

  2003cited by this paper
• The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients.

  2003cited by this paper
• Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.

  2003cited by this paper
• Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.

  2003cited by this paper
• Characteristics of human prostasomes isolated from three different sources

  2003cited by this paper
• Survivin and apoptosis control.

  2003cited by this paper
• Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patients

  2003cited by this paper
• EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes.

  2003cited by this paper
• Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination

  2003cited by this paper
• Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  2003cited by this paper
• Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

  2003cited by this paper
• Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

  2003cited by this paper
• Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.

  2003cited by this paper
• Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

  2003cited by this paper
• Inflammation and cancer

  2002cited by this paper
• Identification of Naturally Processed CD4 T Cell Epitopes from the Prostate-Specific Antigen Kallikrein 4 Using Peptide-Based In Vitro Stimulation1

  2002cited by this paper
• CTLA-4: new insights into its biological function and use in tumor immunotherapy

  2002cited by this paper
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

  2002cited by this paper
• Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients

  2002cited by this paper
• Clinical predictors of androgen-independent prostate cancer and survival in the prostate-specific antigen era.

  2002cited by this paper
• High-Affinity HLA-A(*)02.01 Peptides from Parathyroid Hormone-Related Protein Generate In Vitro and In Vivo Antitumor CTL Response Without Autoimmune Side Effects1

  2002cited by this paper
• Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.

  2002cited by this paper
• Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

  2002cited by this paper
• Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

  2002cited by this paper
• Prostate specific antigen inhibits immune responses in vitro: a potential role in prostate cancer.

  2002cited by this paper
• Systematic review and meta‐analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

  2002cited by this paper
• Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen.

  2002cited by this paper
• Androgen receptor signaling in androgen-refractory prostate cancer.

  2001cited by this paper
• A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line

  2001cited by this paper
• Identification of T helper epitopes from prostatic acid phosphatase.

  2001cited by this paper
• T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

  2001cited by this paper
• Inflammatory-type responses after exposure to ionizing radiation in vivo: a mechanism for radiation-induced bystander effects?

  2001cited by this paper
• A listing of human tumor antigens recognized by T cells

  2001cited by this paper
• Insulin-like Growth Factors and Prostate Cancer

  2001cited by this paper
• Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients.

  2001cited by this paper
• Cancer burden in the year 2000. The global picture.

  2001cited by this paper
• Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.

  2001cited by this paper

• Genetic Bias, Diversity Indices, Physiochemical Properties and CDR3 Motifs Divide Auto-Reactive from Allo-Reactive T-Cell Repertoires

  2021cites this paper
• Immunotherapy against cancer: A comprehensive review

  2016cites this paper
• Effect of multipeptide vaccination therapy on disease outcome of patients with prostate cancer and biochemical recurrence

  2016cites this paper
• A Review on Immunotherapy against Cancer

  2016cites this paper
• Vecteurs d'expression d'antigènes associés à la prostate

  2014cites this paper
• A generalised prey-predator type model of immunogenic cancer with the effect of immunotherapy

  2013cites this paper
• Immunotherapy and Immune Evasion in Prostate Cancer

  2013cites this paper
• Don't run before you can walk

  2012cites this paper
• Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes

  2011cites this paper
• Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models

  2010cites this paper
• The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer.

  2010cites this paper
• Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity.

  2010cites this paper
• Multipeptide vaccination in cancer patients

  2009cites this paper
• Immunogenicity of 56°C and UVC‐treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells

  2009cites this paper
• Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

  2009influential citation
• High frequency of prostate antigen‐directed T cells in cancer patients compared to healthy age‐matched individuals

  2009cites this paper
• Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.

  2009cites this paper
• Genotypic Confirmation of Transimmunization-Induced Dendritic Cell Maturation

  2009cites this paper
• Inhibitory Effect of Matrine on the Expression of PSA and AR in Prostate Cancer Cell line LNCaP

  2008cites this paper
• Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.

  2008cites this paper
• Inhibitory effect of matrine on the expression of PSA and AR in prostate cancer cell line LNCaP

  2008cites this paper
• Vasculature‐targeted tumor necrosis factor‐alpha increases the therapeutic index of doxorubicin against prostate cancer

  2008cites this paper
• Composition pour traiter le cancer de la prostate (pca)

  2007cites this paper
• New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients.

  2007cites this paper
• Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD 4 + CD 25 + Regulatory T Cells

  2007cites this paper
• The prostate‐associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21

  2007cites this paper